196 results about "Ornithine aspartate" patented technology

Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.)

The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning. Preferably, the composition of bio-active compounds includes a combination of 4-hydroxyisoleucine with at least one amino acid selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate and tyrosine. In one presently preferred embodiment of the present invention, the combination is derived, isolated, and/or extracted from fenugreek seeds. Methods for using a novel composition of bio-active compounds from fenugreek seed for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells, promoting muscle function and growth, promoting glycogen synthesis, enhancing glucose disposal, stimulating pancreatic beta cells, promoting metabolic recovery, promoting muscle recovery, promoting lean body mass, and promoting fat burning are also disclosed, wherein methods comprise the steps of: (1) providing an effective amount of a composition of bio-active compounds derived, isolated, and/or extracted from fenugreek seeds; and (2) administering the composition to a human or animal.

The invention provides a method of synthesizing a diketopiperazine of the formula:

wherein:

• • R¹ is —CH₂COR³, or —CH₂CH₂COR³;
  • R² is the side chain of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, phenylalanine, tyrosine, tryptophan, thyroxine, cysteine, methionine, norvaline and ornithine;
  • R³ is —OH, —NH₂, —OR⁴, —NHR⁴, or —NR⁴R⁴; and
  • each R⁴ is independently an alkyl, aryl, alkylaryl, or arylalkyl.

The present invention is directed to novel compositions of bio-active compounds comprising 4-hydroxyisoleucine and one or more compounds selected from the group of amino acids, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Preferably, the novel compositions of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, proline, lysine, histidine, and gamma-aminobutyrate. The composition of bio-active compounds preferably include between about ten percent and about seventy percent of 4-hydroxyisoleucine and between about twenty percent and about forty percent of other amino acids. The bio-active compounds of the novel composition of the present invention may be derived, isolated, and/or extracted from Fenugreek seeds. A preferred method for extracting the bio-active compounds from Fenugreek seeds includes the steps of: (1) providing a plurality of Fenugreek seeds; (2) preparing the Fenugreek seeds; and (3) extracting a novel composition of bio-active compounds from the Fenugreek seeds, which include a preliminary extraction step and a secondary extraction step. The compositions of bio-active compounds have been found to be helpful in restoring healthy energy balance in humans and animals, aiding in weight management efforts, and for balancing blood sugar levels by way of assisting the body to make more efficient use of existing (i.e., endogenous) insulin.

Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, an ECM protein, or a biologically active fragment or variant thereof such as elastin, fibronectin, vitronectin, laminin, collagen I, collagen III, collagen IV, and collagen VI. Also, optionally present on the surface is an active factor, preferably a polycationic polymer or a biologically active fragment or variant thereof, such as polyethyleneimine (PEI), poly-D-lysine (PDL), poly-L-lysine (PLL), poly-D-ornithine (PDO) or poly-L-ornithine (PLO). This surface is used in cell culture to promote cell attachment, survival, and/or proliferation of primary liver cells. The invention also relates to methods utilizing this surface, such as methods for attachment, survival, and/or proliferation of cells. Further disclosed is the use of the surface in cell culture with serum-free medium. Methods of screening using the surface of the invention are also disclosed.

A compound preparation consists of ornithine or its salt and asparagic acid or its salt as well as proper amount of supplementary material; and is prepared into oral preparation or injection through mechanical mixing and other process. The said compound preparation is used for treating various acute hepatitis, chronic hepatosis and hepatic encephacopathy and has the obvious effects of protecting liver and strengthening physique. The preparation process is simple, short in production period and low in cost.

Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).

The invention discloses a metabolism marker for screening and monitoring a colorectal cancer. The metabolism marker is beta-hydroxybutyrate, 5-hydroxytryptamine, lysophosphatidyl choline (C14:0), lysophosphatidyl choline (C16:1), alpha-ketobutyrate, fumaric acid, aspartic acid, 2-octene diacid, glycerin, glyceric acid, tryptophan, aconitate, citric acid, ornithine, glycerol monopalmitate, creatinine, methionine and citrulline. The invention also provides a kit with auxiliary functions of early diagnosis and prognosis monitoring on the colorectal cancer. The application of the micromolecule metabolism marker to monitoring of the colorectal cancer not only greatly improves the accuracy, but also has great guiding significance for development of a subsequent clinical application study.

The present invention provides novel polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like), and methods of using same in the treatment of HIV.

The present invention relates to the treatment of wounds by the topical administration of arginine or ornithine to wound sites. There is described herein a wound healing enhancing medicinal composition formulated from the amino acid arginine or a by-product thereof. Topical application of the medicinal composition to the wound site enhances wound healing by increasing collagen biosynthesis. A medical composition of the present invention may be administered alone, on dressings, or in combination with common vehicles for topical application including, for example, oil-based emulsions, gels, creams, ointments, and the like.

A composition comprising an amphoteric or pseudo-amphoteric agent and a polyhydroxy alpha hydroxyacid existing as a free acid, lactone, or salt, and isomeric or non-isomeric forms thereof is provided. The amphoteric or pseudo-amphoteric agent can be selected from amino acids, dipeptides, aminoaldonic acid, aminouronic acid, lauryl aminoproplyglycine, aminoaldaric acid, neuraminic acid desulfated heparin, deacetylated hyaluronic acid, hyalobiuronic acid, chondrosine, deacetylated chondroitin, creatine, creatinine, hydroxyproline, homocysteine, homocystine, homoserine, ornithine, citrulline, phosphatidylserine, and sphingomyelin. The composition may contain other additives, including cosmetic or pharmaceutical agents for topical treatment of dermatological disorders.

The invention discloses a preparing method of bifidobacteria bacterial active agent and single-purpose protecting agent, which is characterized by the following: allocating 0.01-5.0 wt glycerin, 0.1-6.0 wt polyvinyl pyrrolidon, 0.1-5.0 carbowax, 1.0-10.0 wt skimmed milk powder, 0.5-15.0 wt mycose, 0.1-5.0 wt glutavene, 0.1-5.0 wt L-aspartic acid, 0.1-5.0 wt vitamin C sodium and 0.1-5.0 wt ornithine hydrochlorate. This invention solves the problem of preservation difficulty at normal temperature with conventional method.

The present invention provides a soybean peptide beverage whose composition includes (by weight portion ratio) cane sugar 36000-14000000, oligo maltose 24000-9600000, soybean oligopeptide 19000-760000, ornithine 400-19000 and creatine 2000-100000. Besides, said invention also provides health-care functions of said soybean peptide beverage.

Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.

A prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which may occur in humans or animals upon loading of exercise or stress or the like is provided.

According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a salt thereof as active ingredients can be provided.

Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.

The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.

The invention relates to an ornithine aspartate compound and a novel method thereof. L-aspartic acid and L-ornithine acetate are used as starting materials. The method comprises the following steps of: removing ammonium acetate serving as an intermediate product through solubility differences of ornithine and the ammonium acetate in acetone to obtain free alkali of the ornithine; and reacting thefree alkali with the L-aspartic acid to generate the ornithine and aspartate compound. The synthetic method of the ornithine and aspartate compound has the advantages of low cost, simple process, high purity of the obtained product and easy industrial production.

The invention relates to a preparation process of ornithine aspartate for injection. According to the preparation process, a one-step operation of concentration, desalination and purification is carried out on the obtained reacted raw material liquid. The process used in the invention, which has the advantages of simplicity, short production period, and low energy consumption, is very suitable for the industrialized production of ornithine aspartate injections.

The invention relates to a preparation method of L-ornithine-L-aspartate, which comprises the following steps: mixing L-ornithine hydrochloride and deionized water; adding anion exchange resin and continue stirring to obtain a mixed solution; detecting chloride ion content by utilizing a silver nitrate solution; then adding aspartate; removing the resin and concentrating the filtrate after stirring reaction is ended; adding activated carbon for decoloration and dropwise adding absolute ethyl alcohol; then cooling the decolorized filtrate to the room temperature for separating out crystal; and drying the obtained crystal for 8-30h after the filtering is ended. Compared with the prior art, the preparation method does not generate exhaust gas or waste residues, generates low amount of waste water, basically does not need COD (chemical oxygen demand) and BOD (biochemical oxygen demand), almost does not pollute the environment and has high total product yield which can reach more than 80 percent, does not use poisonous raw materials and has higher product quality.

The invention relates to a method for preparing L-ornithine-L-aspartate salt. The L-ornithine-L-aspartate salt is produced through conversion of arginase. The method comprises the following process steps of: (1) preparing immobilized enzyme; (2) optimizing conversion conditions; and (3) extracting product and refining. Compared with the prior art, the method has the advantages that: production cost is low, the production conditions are mild, impurities in a conversion system are a few, the process steps are simple, the production operation is safe, the purity is high, 300 to 320g of L-ornithine-L-aspartate salt is contained in each liter of reaction solution, the yield is high, the conversion rate of arginase is over 95 percent and the like.